IOVA - CIK 0001425205
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported net income of -$391.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$391.00M | -5.1% |
| FY 2024 | -$372.20M | +16.2% |
| FY 2023 | -$444.00M | -12.1% |
| FY 2022 | -$395.90M | -15.7% |
| FY 2021 | -$342.30M | -31.9% |
| FY 2020 | -$259.58M | -31.4% |
| FY 2019 | -$197.56M | -59.9% |
| FY 2018 | -$123.58M | -34.2% |
| FY 2017 |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported net income of -$391.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, IOVANCE BIOTHERAPEUTICS, INC.'s net income declined from -$25.69M to -$391.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$92.06M |
| -74.1% |
| FY 2016 | -$52.89M | -91.2% |
| FY 2015 | -$27.66M | -129.8% |
| FY 2014 | -$12.04M | +52.6% |
| FY 2013 | -$25.38M | -667.4% |
| FY 2012 | -$3.31M | +87.1% |
| FY 2011 | -$25.69M | - |